Scilex Holding Co - 15 Jun 2026 Form 4 Insider Report for Semnur Pharmaceuticals, Inc. (SMNR)

Reporting relationship: 10%+ Owner
Issuer ticker: SMNR
Reported as of: 15 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Jun 2026, 16:19:45 UTC
Prior SEC filing: 14 Jan 2026
Next SEC filing: 24 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Henry Ji, Scilex Holding Company, Chief Executive Officer, President and Chairperson

Key filing fact

Scilex Holding Co filed Form 4 for Semnur Pharmaceuticals, Inc. (SMNR) on 26 Jun 2026.

Key facts

This page summarizes Scilex Holding Co's Form 4 filing for Semnur Pharmaceuticals, Inc. (SMNR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 26 Jun 2026, 16:19.

Change

Previous filing in this sequence was filed on 14 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (2)

CIK 0001820190 Primary reporting owner

Scilex Holding Co

Relationship: 10%+ Owner
Address: 960 SAN ANTONIO RD, PALO ALTO
Signature: /s/ Henry Ji, Scilex Holding Company, Chief Executive Officer, President and Chairperson
Signature date: 26 Jun 2026

CIK 0002084647

Scilex, Inc.

Relationship: 10%+ Owner
Address: 960 SAN ANTONIO RD, PALO ALTO
Signature: /s/ Henry Ji, Scilex, Inc., Chief Executive Officer and President
Signature date: 26 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SMNR transaction

Common Stock

Other

Transaction value
Shares: -7,034,737
Change %: -3.9%
Price: $0.000000^*
Shares after: 174,770,112
Date: 15 Jun 2026
Ownership: By Scilex, Inc.
Footnotes: F1, F2

SMNR transaction

Common Stock

Other

Transaction value
Shares: -7,034,737
Change %: -3.9%
Price: $0.000000^*
Shares after: 174,770,112
Date: 15 Jun 2026
Ownership: By Scilex, Inc.
Footnotes: F1, F2

SMNR holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 500,000
Date: 15 Jun 2026
Ownership: Direct

SMNR holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 500,000
Date: 15 Jun 2026
Ownership: Direct

SMNR holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 6,250,000
Date: 15 Jun 2026
Ownership: By Scilex Bio, Inc.

SMNR holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 6,250,000
Date: 15 Jun 2026
Ownership: By Scilex Bio, Inc.

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

On June 15, 2026, the Reporting Person paid its previously announced stock dividend (the "Dividend") consisting of an aggregate of 13,972,900 shares of common stock of Semnur Pharmaceuticals, Inc. ("Semnur") held by the Reporting Person (the "Dividend Shares") to record holders of (i) the Reporting Person's common stock, (ii) certain warrants to purchase the Reporting Person's common stock and (iii) certain notes convertible into shares of the Reporting Person's common stock as of June 1, 2026 (the "Record Date" and the holders referenced in clauses (ii) and (iii), the "Additional Participating Holders").

Footnote F2

An aggregate of 6,938,163 Dividend Shares are being held in abeyance by the Reporting Person for the benefit of the Additional Participating Holders who may be entitled to such shares pursuant to the terms of the applicable warrants and convertible notes following the exercise or conversion thereof, and at the time such shares are distributed to the applicable warrantholders and noteholders, the Reporting Person will file a Form 4 reporting such distribution.